If recommended by the US Department of Health and Human Services, spinal muscular atrophy screening will potentially be adopted on the state level.
Revenues in PerkinElmer's diagnostics business rose 23 percent in Q4, thanks largely to its acquisition of autoimmune diagnostic testing firm Euroimmun.
Among the firms reporting, BGI talked about plans to cut down the time and cost of its WGS service, and Invitae's CEO made a surprising proclamation about genetic testing.
The partners will use whole-genome sequencing to investigate the molecular pathways involved in GNE myopathy, a progressive muscle-wasting disease.
There were fewer mergers and acquisitions in the omics space in 2017, breaking a two-year streak of growth — however, the deals themselves stayed fairly large.
The company beat analyst estimates on the top and bottom lines, and said sales from its diagnostics business rose 13 percent year over year.
The index gained more than 3 percent, significantly outperforming the Nasdaq Biotechnology Index, but slightly underperforming the Dow and Nasdaq.
The combined workflow will enable the analysis of archival dried blood spots using 10x Genomics' linked-read technology, according to the companies.
PerkinElmer Genetics will provide clinical whole-genome sequencing, data interpretation, and diagnostic reports to IDG for patients with neurological disorders.
Last week, the company launched whole-genome sequencing of children for customers of its ViaCord cord blood and tissue banking business.
He Jiankui is no longer affiliated with Direct Genomics Biotechnology, the single molecule sequencing company he founded, Nikkei Asian Review reports.
23andMe is offering early customers re-testing on newer chips for a fee, Wired reports.
Newsweek writes about the hopes for precision medicine in cancer, but also challenges getting it to patients.
In Genome Research this week: genomic architecture of glioblastoma, predictive computational approach to estimate SNP fitness, and more.